Evidence map›Paper›PMID 42565372›Full record

SynthesisBJS open2026

Laparoscopic versus open surgery for rectal cancer: individual patient data meta-analysis of the ALaCaRT and Z6051 randomized trials.

Kilian G M Brown, Andrew R L Stevenson, Michael J Solomon, James Murray, Kate Wilson, Val Gebski, James Fleshman, Qian Shi, Thomas E Read, John Simes

Abstract readMeta-AnalysisComparative Study
In one paragraph

Synthesis in BJS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kilian G M BrownDepartment of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.ORCID 0000-0003-0967-8515
Andrew R L StevensonDepartment of Colorectal Surgery, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Michael J SolomonDepartment of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.ORCID 0000-0002-5602-6045
James MurrayFaculty of Medicine and Health, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.
Kate WilsonSurgical Outcomes Research Centre (SOuRCe) and Institute of Academic Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Val GebskiFaculty of Medicine and Health, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.ORCID 0000-0001-8748-1844
James FleshmanDepartment of Surgery, Baylor University Medical Center, Dallas, Texas, USA.
Qian ShiDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-4640-8832
Thomas E ReadDepartment of Surgery, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii, USA.
John SimesFaculty of Medicine and Health, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.

Funding

Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
Washington University/ Siteman Cancer Center Lead Academic SiteU10CA180833 · NCI · WASHINGTON UNIVERSITY · PI BARTLETT, NANCY L, KOZOWER, BENJAMIN D · 2014 to 2018
$7.6M
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic SiteU10CA180790 · NCI · MAYO CLINIC ROCHESTER · PI ALBERTS, STEVEN R, BOUGHEY, JUDY CAROLINE · 2014 to 2018
$6.6M
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)U10CA180858 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUNT, KELLY K, PINNIX, CHELSEA CAMILLE · 2014 to 2018
$5.6M
Colorectal Surgical Society of Australia and New ZealandNational Health and Medical Research Council 1009973National Health and Medical Research Council APP1078113NCI NIH HHS U10 CA180790NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180833NCI NIH HHS U10 CA180858NCI NIH HHS U10 CA180882NIH HHS U10CA18036NIH HHS U10CA180790NIH HHS U10CA180821NIH HHS U10CA180833NIH HHS U10CA180858NIH HHS U10CA180882
6 · The paper itself

Abstract

backgroundThe multicentre ALaCaRT and ACOSOG Z6051 randomized trials were unable to demonstrate non-inferiority of laparoscopic versus open surgery for rectal cancer with respect to a composite pathology metric indicating successful resection. Neither trial was individually powered to detect differences in long-term recurrence or survival. This planned meta-analysis determined long-term oncological outcomes of laparoscopic versus open proctectomy for rectal adenocarcinoma.

methodsThis prospective meta-analysis included individual patient data from patients with cT1-3 N0-2 M0 rectal adenocarcinoma enrolled in the ALaCaRT and ACOSOG Z6051 trials. Pathologically successful resection was defined as complete or near-complete total mesorectal excision, a clear circumferential resection margin (CRM; > 1 mm), and a clear distal resection margin (> 1 mm). The non-inferiority margin for disease-free survival (DFS) was an absolute difference of 5% at least 3 years after surgery.

resultsThe combined data set included 935 patients (65.6% men, mean age 60.7 years, mean body mass index 26.7 kg/m2) randomized to open (457 patients) or laparoscopic (478 patients) proctectomy. Pathologically successful resection was lower in the laparoscopic than open group (85.1% versus 89.9%, respectively; pooled estimate 4.6% difference; 95% confidence interval (c.i.) -8.6% to -0.5%). The median follow-up was 60.2 (interquartile range 49.9-61.1) months. Three-year DFS was 75.2% (95% c.i. 71.1% to 79.2%) and 76.5% (95% c.i. 72.5% to 80.6%) for the laparoscopic and open groups, respectively (pooled estimate difference -1.5%; 95% c.i. -7.2% to 4.2%). Non-inferiority of laparoscopic surgery was not demonstrated because the lower one-sided 95% c.i. (-6.3% to 100%) crossed -5%. Three-year locoregional recurrence was higher in laparoscopic than open group (5.4% (95% c.i. 3.3% to 7.5%) versus 2.0% (95% c.i. 0.7% to 3.4%), respectively; pooled estimate 3.1% difference (95% c.i. 0.6% to 5.6%)). A clear CRM was the most significant and only pathological predictor of both DFS (P < 0.0001) and overall survival (P < 0.0001).

conclusionLaparoscopic proctectomy led to a lower rate of pathologically successful resection and a higher rate of locoregional recurrence at 3 years. The possibility of subsequent poorer DFS or overall survival rate requires further evaluation, because this analysis was not specifically powered for these endpoints.

Indexed as

AdenocarcinomaLaparoscopyProctectomyRectal NeoplasmsAgedDisease-Free SurvivalFemaleHumansMaleMargins of ExcisionMiddle AgedNeoplasm Recurrence, LocalProspective StudiesRandomized Controlled Trials as TopicTreatment Outcomelaparoscopic surgeryproctectomytotal mesorectal excision

Identifiers

PMID42565372
PMCPMC13448722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.